Information Provided By:
Fly News Breaks for February 27, 2020
Feb 27, 2020 | 07:11 EDT
Barclays analyst Carter Gould initiated coverage of Neurocrine with an Equal Weight rating and $105 price target. The analyst initiated coverage of the U.S. Biopharmaceuticals industry with a Positive view citing waning near-term concerns on drug pricing reform, evidence of innovation and attractive valuations. Near-term Ingrezza headwinds and lack of clinical catalysts keeps him "somewhat cautious " on Neurocrine shares/
News For NBIX From the Last 2 Days
There are no results for your query NBIX